Related Experiment Videos
[Amineptine-induced cholestatic hepatitis. 5 cases (author's transl)]
La Nouvelle Presse Medicale
|December 20, 1980
Summary
Amineptine, a tricyclic antidepressant, can cause cholestatic jaundice and liver cell damage (cytolysis). Drug rechallenge in two patients confirmed amineptine
Area of Science:
- Hepatology
- Clinical Pharmacology
- Toxicology
Background:
- Tricyclic antidepressants are widely prescribed for depression.
- New pharmaceutical agents require thorough safety evaluation.
- Drug-induced liver injury (DILI) is a significant clinical concern.
Observation:
- Five cases of cholestatic jaundice with cytolysis were observed during amineptine treatment.
- Patients presented with similar clinical and biochemical profiles.
- No alternative causes for jaundice were identified in the observed cases.
Findings:
- Amineptine was identified as the likely cause of liver injury.
- Reintroduction of amineptine led to rapid symptom recurrence in two patients.
- Evidence suggests a potential immunoallergic mechanism underlying the hepatotoxicity.
Implications:
- Clinicians should be aware of the potential hepatotoxicity of amineptine.
- Further investigation into the safety profile of amineptine is warranted.
- This study highlights the importance of monitoring liver function in patients taking new psychotropic medications.